Overview

Eliquis Regulatory Post Marketing Surveillance (rPMS)

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Apixaban